Breaking News

GigaGen Secures $135M BARDA Contract for Biothreat Therapies

Will advance innovative therapies against naturally emerging and intentional biological threats.

Author Image

By: Charlie Sternberg

Associate Editor

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $135.2 million to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat of interest to the agency that will be determined at a later time.   “We are thrilled to have been award...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters